Nanologica Q2 2023 - Estimates largely maintained
2023-07-10 15:59:00
Redeye maintains its estimates with minor changes following Nanologica’s Q2 2023 report, on which we have a rather neutral take. Sales should start increasing from Q3 onwards, and we see the potential for an eventful H2 for Nanologica, which trades at a discount to our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/